BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
PRAX-628 Phase 2 study for treatment of focal epilepsy expected to initiate in 4Q23 BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback